A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results